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Abstract
Most synthetic bone grafts are either hard and brittle ceramics or paste-like materials that differ in applicability 
from the gold standard autologous bone graft, which restricts their widespread use. Therefore, the aim 
of the study was to develop an elastic, highly porous and biodegradable β-tricalciumphosphate/poly(L-
lactide-co-ε-caprolactone) (β-TCP/PLCL) composite for bone applications using supercritical CO2 foaming. 
Ability to support osteogenic differentiation was tested in human adipose stem cell (hASC) culture for 21 d. 
Biocompatibility was evaluated for 24 weeks in a rabbit femur-defect model. Foamed composites had a 
high ceramic content (50 wt%) and porosity (65-67 %). After 50 % compression, in an aqueous environment 
at 37 °C, tested samples returned to 95 % of their original height. Hydrolytic degradation of β-TCP/PLCL 
composite, during the 24-week follow-up, was very similar to that of porous PLCL scaffold both in vitro and 
in vivo. Osteogenic differentiation of hASCs was demonstrated by alkaline phosphatase activity analysis, 
alizarin red staining, soluble collagen analysis, immunocytochemical staining and qRT-PCR. In vitro, hASCs 
formed a pronounced mineralised collagen matrix. A rabbit femur defect model confirmed biocompatibility 
of the composite. According to histological Masson-Goldner’s trichrome staining and micro-computed 
tomography, β-TCP/PLCL composite did not elicit infection, formation of fibrous capsule or cysts. Finally, 
native bone tissue at 4 weeks was already able to grow on and in the β-TCP/PLCL composite. The elastic 
and highly porous β-TCP/PLCL composite is a promising bone substitute because it is osteoconductive and 
easy-to-use and mould intraoperatively.
Keywords: Bone substitute, composite, adipose stem cells, osteogenic differentiation, rabbit distal femur 
defect, β-tricalciumphosphate, poly(L-lactide-co-ε-caprolactone).
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Introduction
Bone is the second most commonly transplanted 
tissue, with approximately 2.2 million orthopaedic 
surgeries carried out worldwide annually (Campana 
et al., 2014; Kinaci et al., 2014; Van der Stok et al., 2011). 
As people age, this number is expected to rise. Among 
bone transplants, autologous bone is considered 
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the gold standard, while allogenic bone and bone 
substitutes are also used. Important patient groups 
affected by problems concerning bone transplants 
are young children, who do not have enough bone 
tissue to be harvested, and elderly people, whose 
bone quality is weak. In addition, several problems 
are related to the use of autologous bone transplants, 
such as morbidity of the harvesting site, insufficiency 
and viability of the harvested bone and infection 
(Freeman and McNamara, 2017; Van der Stok et al., 
2011). Furthermore, even though allograft bone may 
provide enough bone, transplanted tissue might be 
rejected; also, proteins and osteoinductive factors 
might be denaturated following sterilisation (Boyce 
et al., 1999). Moreover, when using allografts, disease 
transmission and infection are recurring problems, as 
18 % of donated femoral heads have been shown to 
be affected by bacterial or fungal infections (Barbour 
and King, 2003; Boyce et al., 1999; Freeman and 
McNamara, 2017). Therefore, there is an evident and 
growing need for safe, synthetic bone transplants and 
tissue engineering strategies.
 Even though various biomaterials have been 
proposed for bone replacement, the study and 
development of these structures have rarely 
proceeded to clinical applications (de Misquita et 
al., 2016). Before a bone substitute can become a 
clinically used product, its efficacy and safety has to 
be demonstrated both in vitro and in vivo as well as 
in a clinical trial. According to the regulation (EU) 
2017/745 of the European Parliament and of the 
Council of 5 April 2017 on medical devices, a product 
cannot receive a CE mark without clinically proven 
data (Web ref. 1). An ideal bone substitute should be 
osteoconductive or osteoinductive, biocompatible, 
biodegradable (Van der Stok et al., 2011) and highly 
porous, with a pore size larger than 250 µm to allow 
cell and tissue ingrowth (Mathieu et al., 2005; Turnbull 
et al., 2017; Zadpoor, 2015) and vascularisation 
(Rouwkema et al., 2008). Furthermore, the implant 
should not induce the formation of fibrotic tissue 
(Van der Stok et al., 2011) or infection. Cost-effective, 
large-scale manufacturing is also important when 
designing a new bone substitute for clinical use.
 Ceramics, such as hydroxyapatite and other 
calcium phosphates, are highly compatible with 
bone tissue and, therefore, the most widely used 
synthetic bone substitute materials for treating 
large bone defects. Among calcium phosphates, 
β-tricalciumphosphate (β-TCP) induces significantly 
more bone in an ectopic site in vivo as compared 
to hydroxyapatite (Chatterjea et al., 2013; Yuan et 
al., 2010) and, therefore, β-TCP was chosen as the 
calcium phosphate phase of the composite. However, 
there has been conflicting results concerning the 
osteoinductive properties of β-TCP and speculation 
that they might vary according to the surface 
properties of the material (Bohner and Miron, 2019; 
Duan et al., 2018). Calcium phosphate materials 
are hard and brittle, making them difficult to 
shape intraoperatively and implant. Synthetic 
polymers such as polylactide, polyglycolide, poly-ε-
caprolactone and their copolymers are biocompatible 
and support osteogenic differentiation of stem cells in 
vitro (Campana et al., 2014; Jeong et al., 2008; Temple 
et al., 2014; Wang et al., 2016). Poly(L-lactide-co-ε-
caprolactone) (PLCL) is a copolymer of L-lactide and 
ε-caprolactone with highly desirable characteristics as 
an implant material: elasticity, flexibility, high tensile 
strength, controllable degradation rate and good 
biocompatibility (Holmbom et al., 2005; Wang et al., 
2016). PLCL scaffolds have been used in bone tissue 
engineering although, as PLCL is inert, hydrophobic 
and lacks biological recognition sites, the interaction 
with tissue and cells is not good enough either in vitro 
or in vivo (Jeong et al., 2008; Wang et al., 2016). By using 
supercritical CO2 (scCO2) processing, it was possible 
to create a homogenous, porous composite of the 
bioactive β-TCP and elastic PLCL. scCO2 foaming was 
chosen as the processing technique as it is easy, cost-
effective and non-toxic. Furthermore, the technique 
enables the production of polymeric structures with 
different pore sizes and total porosities. Briefly, 
CO2 becomes a supercritical fluid above its critical 
temperature and pressure (31.10 °C, 73.9 bar), 
adapting characteristics between a liquid and a gas. 
Polymeric materials can be dissolved in scCO2 and, 
as the pressure is decreased controllably, the CO2 gas 
nucleation and expansion creates the wanted porous 
structure inside the polymeric material (Mathieu et 
al., 2005).
 Multipotent human adipose stem cells (hASCs) 
are easily available. Furthermore, hASCs have been 
widely studied in the field of bone tissue engineering 
in vitro (Kyllönen et al., 2013a; Kyllönen et al., 2013b; 
Ojansivu et al., 2015; Tirkkonen et al., 2013; Vanhatupa 
et al., 2015) and in vivo (Jeon et al., 2008; Wilson et al., 
2012). Therefore, hASCs are a relevant cell type for 
studying both the cytocompatibility of a potential 
bone substitute and the ability of a scaffold to support 
osteogenic differentiation in vitro.
 The aim of the current study was to overcome 
the major limitations of previous bone-application-
intended materials, to develop an elastic, highly 
porous, biodegradable and biocompatible β-TCP/
PLCL composite for bone applications by using 
scCO2 and to test its performance both in vitro and in 
vivo. Furthermore, the aim was to create a composite 
mimicking the mechanical properties of cartilaginous 
soft callus, which serves as the natural scaffold for 
bone regeneration during bone healing. For the first 
time, it was shown that scCO2 processing of β-TCP/
PLCL composite with a high ceramic content (50 wt%) 
could be used to produce scaffolds with porosity 
as high as 65-67 %. Furthermore, β-TCP granules 
were brought to the surface of the composites by 
a dynamic compression treatment. In vitro studies 
with hASCs demonstrated both cytocompatibility 
and osteogenic capacity of the scaffold. Furthermore, 
biocompatibility, osteoconductivity and bone tissue 
ingrowth were shown in vivo in a rabbit femur defect 
model.
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Materials and Methods
Composite manufacturing and characterisation
Composites were manufactured by melt-mixing 
PLCL-polymer (70L/30CL; Purasorb PLC7015, 
Corbion Purac Biomaterials, Gorinchem, the 
Netherlands) with 50 wt% β-TCP, having a particle 
size range between 100 and 300 µm (Plasma Biotal 
Ltd., Buxton, UK). Composites were foamed using 
scCO2, as described in the granted patent (Web ref. 
2), by using a Supercritical Carbon Dioxide Reactor 
System (SFE250, Waters Ltd., MA, USA). The residual 
lactide monomer content was measured by gas 
chromatography (DC8000, CE Instruments, Rodano, 
Italy) after post-melting. Foamed blocks were cut into 
discs for in vitro studies [diameter (Ø) = 8 mm, height 
(h) = 3 mm)] and into cylinders for in vivo studies 
for cancellous bone (Ø = 3.2 mm, h = 10 mm) and 
intramuscular implantation (Ø = 4.0 mm, h = 10 mm). 
All samples were sterilised by γ-irradiation with a 
minimum dose of 25 kGy.
 Prior to in vitro and in vivo studies, elastic scaffolds 
were treated by dynamically pre-compressing them 
repeatedly in an aqueous environment at 37 °C for 
a minimum of 20 cycles and compression level of 
at least 50 %. Composites were imaged by using a 
scanning electron microscope (SEM; Philips XL-30) 
and Xradia MicroXCT-400 X-ray imaging system with 
a voxel size of 5.6 µm (Carl Zeiss X-ray Microscopy 
Inc.) before and after the compression treatment. 
Porosities and pore sizes were calculated from 
micro-computed tomography (µCT) images with 
Fiji (Schindelin et al., 2012) using BoneJ (Doube et al., 
2010) plugin. All the visualisations were conducted 
with Avizo 9.3.0 Software (Thermo Fisher Scientific).
Mechanical testing of composites
Mechanical testing was performed for both intact and 
pre-compressed samples (Ø = 8 mm, h = 3.5 ± 0.6 mm), 
as dry at room temperature (RT) and in an aqueous 
environment at 37 °C using the Instron Electropuls 
E1000 (High Wycombe, UK) by compressing 
unconfined samples 1 mm/min until a 50 % strain was 
reached. Used crosshead speed was adapted from the 
standard ISO 604. Elastic modulus was determined 
from linear section of the stress-strain curve, between 
0 and 20 % strain.
Hydrolytic degradation of composites in vitro and 
in vivo
Hydrolytic degradation of the porous composites 
in vitro was studied at 4, 12 and 24 weeks at 37 °C 
in Sörensen buffer solution (n = 6) and in vivo as 
intramuscular implantation on underside of the 
supraspinatus muscle (n = 6 at 4 and 12 weeks; n = 1 
at 24 weeks due to strong scaffold degradation). A 
porous PLCL (70/30) polymer scaffold was used 
as a reference. Degradation was monitored by size 
exclusion chromatography (SEC) utilising a Waters 
Associates system equipped with a Waters 717Plus 
Satellite autosampler, a Waters 510 HPLC solvent 
pump, two linear PL gel 5 µm columns connected in 
series and a Waters 2414 differential refractometer. 
The number-average molecular weight (Mn), weight-
average molecular weight (Mw) and polydispersity 
of the samples were determined against polystyrene 
standards at RT. Chloroform was used as the eluent 
and was delivered at a flow rate of 1 mL/min. 
Samples were dissolved in chloroform at a polymer 
concentration of 13.5 ppm. The injection volume was 
100 mL.
Isolation, characterisation and seeding of hASCs 
in vitro
hASCs were isolated from adipose tissue samples 
obtained from three female donors (40 ± 11 years old) 
undergoing surgical procedures at the Department 
of Plastic Surgery, Tampere University Hospital after 
patients gave their consent. The study was conducted 
in accordance with the Ethics Committee of the 
Pirkanmaa Hospital District, Tampere (R15161).
 Isolation of hASCs was conducted using a 
mechanical and enzymatic protocol as described 
previously (Lindroos et al., 2009). Isolated hASCs 
were expanded in basic medium (BM) consisting 
of Dulbecco’s modified Eagle’s medium: nutrient 
mixture F-12 (DMEM/F-12 1 : 1; Thermo Fischer 
Scientific), 5 % human serum (HS; BioWest, Nuaillé, 
France), 1 % antibiotics (100 U/mL penicillin; 100 U/
mL streptomycin; Lonza) and 1 % L-glutamine 
(GlutaMAX I; Thermo Fischer Scientific). hASCs 
were cultured at 37 °C in 5 % CO2 and medium was 
changed twice a week. Cells were detached with 
TrypLE Select (Life Technologies). Experiments were 
carried out at passage 3.
 To verify the mesenchymal origin of the cells, 
surface marker expression of hASCs at passage 1 
was characterised by fluorescent-activated cell sorter 
(FACSAria; BD Biosciences) as described previously 
(Lindroos et al., 2009). Monoclonal antibodies against 
CD14-PE-Cy7, CD19-PE-Cy7, CD45RO-APC, CD73-
PE, CD90-APC (BD Biosciences), CD34-APC, HLA-
DR-PE (Immunotools, Friesoythe, Germany) and 
CD105-PE (R&D Systems) were used. The analysis 
was performed on 10,000 cells per sample and 
unstained hASC samples were used to compensate 
for the background autofluorescence levels. The 
expression of the surface markers CD73, CD90 and 
CD105 was positive, the expression of CD14, CD19, 
CD45 and human leukocyte antigen DR isotype 
(HLA-DR) was negative and that of CD34 was 
moderate (Table 1). The surface markers’ expression 
of hASCs confirmed the mesenchymal origin of the 
cells (Dominici et al., 2006).
 Before cell seeding, sterile composites were pre-
compressed in BM and incubated for 24 h in BM 
at 37 °C. hASCs were seeded in a 50 µL medium 
drop at a density of 510 cells/mm3 into the scaffolds. 
Cells were allowed to attach for 2-3 h before 500 µL 
of BM or osteogenic medium (OM) were added. 
OM consisted of BM with the addition of 250 µM 
ascorbic acid 2-phosphate (Sigma-Aldrich), 10 mM 
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β-glycerophosphate (Sigma-Aldrich) and 5 nM 
dexamethasone (Sigma-Aldrich). As a 2-dimensional 
(2D) control for alizarin red staining, 500 cells were 
seeded in 1 mL of BM or OM in a 24-well plate (Nunc, 
Roskilde, Denmark).
Cell viability and proliferation
Cell viability was evaluated qualitatively by staining 
hASCs with fluorescent live/dead-staining probes 
(Molecular Probes) after 7, 14 and 21 d. hASCs were 
incubated for 45 min at RT with a mixture of 0.5 µM 
calcein acetoxymethyl ester (Molecular Probes) and 
0.25 µM ethidium homodimer-1 (Molecular Probes). 
Images of living cells (green fluorescence) and 
dead cells (red fluorescence) were acquired using 
an Olympus IX51 phase contrast microscope with 
fluorescence optics and Olympus DP30BW camera 
(Olympus).
 Cell number was analysed quantitatively after at 
7, 14 and 21 d by analysing the total amount of DNA 
by CyQUANT Cell Proliferation Assay Kit (Molecular 
Probes), according to manufacturer’s protocol, as 
reported previously (Kyllönen et al., 2013a). Samples 
were analysed after two freeze-thaw cycles and 
fluorescence was measured at 480/520 nm with a 
microplate reader (Victor 1420 Multilabel Counter; 
Wallac, Turku, Finland).
Analysis of osteogenic differentiation in vitro
Alkaline phosphatase (ALP) activity was determined 
after 7, 14 and 21 d, as described previously (Kyllönen 
et al., 2013a). ALP activity was determined from the 
same cell lysates as total DNA content. Absorbance 
was measured at 405 nm (Victor 1420).
 Soluble total collagen was analysed at 7, 14 and 
21 d by Soluble Collagen Assay Sircol™ (Biocolor, 
Carrickfergus, UK), as described previously 
(Tirkkonen et al., 2013). Briefly, collagen was 
dissolved for 2 h at 4 °C with 0.5 M acetic acid (Merck) 
containing 0.1 mg/mL pepsin (Sigma-Aldrich), while 
gently shaking. Thereafter, 100 µL samples were dyed 
with 500 µL of Sircol™ Dye Reagent (Sirius red in 
picric acid; Biocolor) for 30 min at RT, while gently 
shaking. Then, samples were centrifuged for 10 min at 
13,400 ×g and the dyed collagen pellets were washed 
with 750 µL of ice-cold Acid-Salt Wash Reagent 
(Biocolor). After another 10 min centrifugation at 
13,400 ×g, the dye was diluted by adding 250 µL of 
Alkali Reagent (Biocolor) on top of the dyed collagen 
pellet. Intensity of the dye was measured from two 
parallel 100 µL samples in a 96-well plate (Nunc) 
using a microplate reader (Viktor 1420).
 Mineralisation was studied by alizarin red S 
staining after 14 and 21 d, as described previously 
(Kyllönen et al., 2013a). In brief, paraformaldehyde 
(Sigma-Aldrich)-fixed cell-scaffold constructs were 
stained with filtered 2 % alizarin red S (pH 4.2; Sigma-
Aldrich) and photographed after several washing 
steps. Dye was extracted with cetylpyridinium 
chloride (100 mM, Sigma-Aldrich) and its intensity 
was determined by measuring the absorbance at 
540 nm (Victor 1420).
 Quantitative real-time reverse transcription 
polymerase chain reaction (qRT-PCR) analysis was 
used to compare the relative expression of osteogenic 
genes in different experimental groups. Total RNA 
was isolated from hASCs at 14 and 21 d using the 
NucleoSpin RNA II kit reagent (Macherey-Nagel) 
according to the manufacturer’s protocol. Single-
strand cDNA was synthesised from total RNA using 
the High-Capacity cDNA Reverse Transcriptase Kit 
(Applied Biosystems). Data were normalised to the 
expression of the housekeeping gene human acidic 
ribosomal phosphoprotein large P0 (hRPLP0). Primer 
sequences and accession numbers for RPLP0 and 
osteogenic genes RUNX2a, OSTERIX and DLX5 are 
listed in Table 2. The qRT-PCR mixture contained 
cDNA, primers and SYBR Green PCR Master Mix 
(Applied Biosystems). Reactions were conducted 
with ABI PRISM® 7300 Sequence Detection System as 
reported previously (Kyllönen et al., 2013a). Results 
were processed with ABI PRISM® 7300 Sequence 
Detection System-software (Applied Biosystems).
 Osteogenic marker proteins collagen type I (COL-I) 
and osteocalcin (OCN) were detected with an indirect 
immunocytochemical staining method. At 7, 14 and 
Table 1. Surface marker expression of hASCs at passage 1. Positive > 98 %; negative < 2 %; moderate 
< 50 % > 2 %. SD: standard deviation.
Surface marker mean ± SD expression
CD14 Serum lipopolysaccharide binding protein 0.6 ± 0.6 negative
CD19 B lymphocyte-lineage differentiation antigen 0.4 ± 0.2 negative
CD34 Sialomucin-like adhesion molecule 34.8 ± 32.2 moderate
CD45 Leukocyte common antigen 1.6 ± 0.3 negative
CD73 Ecto-50-nucleotidase 98.2 ± 1.3 positive
CD90 Thy-1 (T-cell surface glycoprotein) 99.8 ± 0.1 positive
CD105 SH-2, endoglin 98.3 ± 1.2 positive
HLA-DR Major histocompatibility class II antigens 0.6 ± 0.1 negative
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buprenorphine (0.03 mg/kg, Bupaq® 0.3 mg/mL, 
Richter Pharma) were used as a pain medication.
 A 20 mm skin incision was made on the lateral 
aspect of the right femoral condyle and a 3.2 mm 
diameter and 10 mm deep drilling hole was made 
above the lateral collateral ligament. Composites 
were moistened and pre-compressed in blood 
collected from the drilling hole prior to implantation. 
The drilling hole was filled with 3.2 × 10 mm 
cylinder-shaped β-TCP/PLCL composite implant and 
periosteum and skin were closed.
 For the degradation study, a skin incision was 
made midline over the spine between the scapulae 
and two 4 × 10 mm β-TCP/PLCL composites 
were inserted through an applicator tube to the 
right supraspinatus muscle and two 4 × 10 mm 
polymer implants to the left supraspinatus muscle. 
Subcutaneous atipametzole (0.75 mg/kg, Antisedan® 
5 mg/mL, OrionPharma) was used to reverse 
the sedative effect of the medetomidine after the 
procedure. For postoperative pain, subcutaneous 
buprenorphine (0.03 mg/kg) and carprophen (4 mg/
kg) were used. Subcutaneous metoclopramide 
(0.2 mg/kg, Primperan® 5 mg/mL, Sanofi Oy, Espoo, 
Finland) was used to increase the intestinal motility. 
Rabbits were in a cage rest for 2 weeks after the 
surgery and, then, in a large-group housing area. 
They had access to hay and water ad libitum. One 
rabbit died during the procedure due to anaesthesia-
related causes and one died 3 d after the operation 
as a result of a complication unrelated to the femoral 
defect.
 The 18 rabbits were randomly divided in groups of 
6 animals and euthanised 4, 12 and 24 weeks after the 
procedure. Subcutaneous injection of medetomidine 
(0.3 mg/kg) and ketamine (35 mg/kg) was followed by 
intracardial injection of pentobarbital (300 mg/rabbit, 
Mebunat® vet 60 mg/mL, Orion Pharma Oy, Espoo, 
Finland). The intramuscular implants were collected 
for further analysis.
 µCT analysis (MicroXCT-400, Zeiss) was 
performed on all the harvested femoral condyles 
21 d, hASCs were fixed with 4 % paraformaldehyde 
(Sigma Aldrich) in Dulbecco’s phosphate-buffered 
saline (DPBS) with 0.05 % Triton-X 100 (Sigma 
Aldrich) for 10 min followed by washing steps. Cells 
were blocked in 1 % bovine serum albumin (BSA) 
in DPBS for 1 h at 4 °C. Primary antibodies mouse 
monoclonal anti-COL-I (dilution 1 : 2,000; Abcam) 
and mouse monoclonal anti-OCN (dilution 1 : 100; 
Abcam) were diluted in 1 % BSA and incubated over 
night at 4 °C. As a negative control, 1 % BSA without 
primary antibody was used. After washing steps, 
secondary antibody donkey anti-mouse AlexaFluor 
488 IgG (dilution 1 : 1,000; Invitrogen) diluted in 1 % 
BSA was added and incubated for 45 min at RT. Cells 
were washed repeatedly and treated with 0.1 % 4, 
6-diamidino-2-phenylindole (DAPI) (Sigma Aldrich) 
in DPBS for 5 min at RT. Finally, cells were washed 
and imaged using an Olympus IX51 phase contrast 
microscope with fluorescence optics and Olympus 
DP30BW camera (Olympus). Images were edited 
with Adobe Photoshop version CS4.
Animal experiments
T h e  F i n n i s h  A n i m a l  E x p e r i m e n t  B o a r d 
(ESAVI/5398/04.10.07/2014) approved the animal 
study and used protocols. 20 female New Zealand 
white rabbits were used.
 Anaesthesia was induced by subcutaneous 
injection of ketamine (35 mg/kg, Ketador vet® 100 mg/
mL, Richter Pharma, Wels, Austria) and medetomidine 
(0.3 mg/kg, Domitor® 1 mg/mL, OrionPharma, Espoo, 
Finland). Intravenous propofol boluses (2-5 mg/
rabbit, Vetofol® 10 mg/mL, Norbrook Laboratories, 
Newry, Ireland), ketamine bolus (10 mg/kg) or 
mask anaesthesia with 1.5 % isoflurane (IsoFlo® 
vet 100%, Abbott Laboratories, Chicago, IL, USA) 
were used during the surgical procedure if needed. 
Intravenous trimethoprim/sulfamethoxazole (15 mg/
kg, Duoprim® 200/40 mg/mL, Intervet International, 
Boxmeer, the Netherlands) was used as an antibiotic 
prophylaxis. Intravenous carprophen (4 mg/kg, 
Norocarp® 50 mg/mL, Norbrook Laboratories) and 
Table 2. Primer sequences and accession numbers of genes analysed by qRT-PCR.
Name Full name
Accession 
number  Sequence
Product 
size (bp)
hRPLP0 Ribosomal 
protein, large, P0
NM_001002
Forward 5’-AAT CTC CAG GGG CAC CAT T-3’
70
Reverse 5’-CGC TGG CTC CCA CTT TGT-3’
hALP Alkaline 
phosphatase
NM_000478.4
Forward 5’-CCC CCG TGG CAA CTC TAT CT-3’
73
Reverse 5’-GAT GGC AGT GAA GGG CTT CTT-3’
hRUNX2A Runx2A, variant 1 NM_001024630.3
Forward 5’-CTT CAT TCG CCT CAC AAA CAA C-3’
62
Reverse 5’-TCC TCC TGG AGA AAG TTT GCA-3’
hOSX Osterix AF_477981
Forward 5’-TGA GCT GGA GCG TCA TGT G-3’
79
Reverse 5’-TCG GGT AAA GCG CTT GGA-3’
hDLX5 Distal-less 
homeobox 5
NM_005221.5
Forward 5’-ACC ATC CGT CTC AGG AAT CG-3’
75
Reverse 5’-CCC CCG TAG GGC TGT AGT AGT-3’
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before histological preparation. Tube voltage of 
120 kV and tube current of 83 µA were selected. From 
each sample, 1,600 projections were taken with a 
13.4 µm voxel size. Exposure time was 4 s. Projections 
were reconstructed with the manufacturer’s 
XMReconstructor software. Image processing and 
analysis were done with Avizo Software (Thermo 
Fisher Scientific). Thereafter, the femoral condyles 
were fixed in 10 % buffered formalin solution 
followed by routine ascending ethanol series and 
methyl methacrylate embedding. A hard-tissue 
microtome (Leica, SM2500) was used to cut 5 µm-
thick slice. Masson-Goldner’s Trichrome (MGT) 
staining was performed.
Statistical analysis
Statistical analysis was performed with SPSS version 
23 (IBM) using a non-parametric test, due to the small 
Fig. 1. β-TCP/PLCL composite characteristics before and after pre-compression treatment. (a) Representative 
SEM (scale bar: 200 µm; PLCL coloured violet; β-TCP coloured pink) and µCT (arrows indicate the granules 
released from under the polymer film; scale bar: 1,000 µm) images. (b) Compressive stress at 20 and 50 % 
strain when dry and 1 h, 7 or 14 d at 37 °C in aqueous environment. (c) Modulus when dry and 1 h, 7 or 
14 d at 37 °C in aqueous environment. Statistical significances indicated as a p ≤ 0.05 (n = 6). 
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sample size. The effects of stress and strain (n = 6) on 
intact and pre-compressed composites and of pre-
compressing and incubation at 37 °C on modulus 
(n = 6) of composites were compared using Mann-
Whitney U-test with Bonferroni correction. Effects 
of BM or OM in combination with the composite on 
cell number, ALP activity, mineralisation, soluble 
collagen amount and gene expression were compared 
using Mann-Whitney U-test with Bonferroni 
correction. Results were considered significant when 
p < 0.05. Experiments for cell number, ALP activity, 
mineralisation and soluble collagen amount were 
repeated with 3 donor lines each with 3 parallel 
samples (n = 9). Experiments for gene expression 
were repeated with 3 donor lines each with 2 parallel 
samples (n = 6).
Results
Characteristics of the composite
Scaffold porosity was 65-67 %, with an average pore 
size of 380 ± 130 µm. In addition, compressive stress 
at 20 and 50 % strain and modulus were analysed at 
different time points. SEM images (Fig. 1a) showed 
that before pre-compression treatment, β-TCP 
(coloured pink) was mainly on the cutting surface of 
the composite, while the surfaces of the pores were 
smooth and a PLCL film (coloured violet) mainly 
covered the β-TCP granules. However, the effect of 
the pre-compression was evident, as after the protocol 
the PLCL surface of the pores had ruptured and 
β-TCP granules protruded through it. Furthermore, 
SEM images demonstrated that the treatment tore 
additional holes in the pores of the composite. µCT 
images agreed with SEM images as they revealed 
that after the treatment more β-TCP granules were on 
display on the pore surfaces or even detached from 
the polymer phase in contrast to intact composite 
(Fig. 1a).
 Both the compression treatment and warming 
at 37 °C had a significant effect on the mechanical 
properties of the composite. The compression 
treatment of a dry composite decreased the modulus 
significantly in contrast to an intact composite, but 
1 h at 37 °C aqueous solution treatment erased such a 
difference (Fig. 1c). The same phenomenon was seen 
in the compressive stress analysis at both 20 and 50 % 
strain (Fig. 1b). Moreover, warming and wetting of the 
intact composite significantly decreased the modulus 
in comparison to dry intact composite (Fig. 1c). 
Intriguingly, both modulus and strength increased 
between 1 h and 7 d in an aqueous environment at 
37 °C (Fig. 1b,c). No samples were broken during 
the compression analysis and samples tested in an 
aqueous environment at 37 °C returned to 95 % of 
their original height after the 50 % compression.
Hydrolytic degradation of the composite in vitro 
and in vivo
Molecular weight (Mn and Mw) change, caused by 
hydrolytic degradation of the polymer chains in 
Fig. 2. Hydrolytic degradation analysis 
results. Mn and Mw of (a) β-TCP/PLCL 
composites and (b) PLCL scaffolds were 
analysed in vitro and in vivo after 4, 12 
and 24 weeks.
42 www.ecmjournal.org
S Pitkänen et al.                                                                      ScCO2-foamed β-TCP/PLCL composite bone substitutes
both β-TCP/PLCL composites (Fig. 2a) and PLCL 
polymer scaffolds (Fig. 2b), was analysed both in 
vitro and in vivo. Mn and Mw of the samples were 
determined at 4, 12 and 24 weeks and the results 
showed that the degradation in vitro was similar to 
that in vivo for both materials. Furthermore, scaffold 
molecular weight had already decreased significantly 
during the first 4 weeks. In addition, Mn and Mw of 
the composite scaffold decreased by approximately 
90 % during the 24-week follow-up. The neat polymer 
scaffold had initial Mn and Mw values higher than 
the composite but the difference in the degradation 
profile was evened out in 4 weeks, after which no 
clear differences were seen between the materials or 
the in vitro and in vivo environments. The residual 
L-lactide content after melt-extrusion and scCO2-
foaming for the PLCL scaffold was 0.09 wt% and for 
the β-TCP/PLCL composite 0.06 wt%.
Viability and proliferation of hASCs in vitro
Cell viability was very good since only single 
dispersed dead cells were observed in cultures. In 
BM, cell number was clearly less than that in OM at 
7 d (Fig. 3) and the difference was evident also at 14 
and 21 d. Cell number was similar in OM at 7 d and 
BM at 21 d.
 Cell proliferation was analysed by fluorescent 
CyQUANT proliferation assay after 7, 14 and 21 d in 
culture. In concordance with the live/dead staining, 
cell number was significantly larger in OM in contrast 
to BM at all time points (Fig. 4a). Moreover, cell 
number as indicated by live/dead staining was similar 
in OM at 7 d and BM at 21 d. Variation among the 
different donor cell lines was evident in proliferation 
analysis, as OM did not increase the proliferation of 
hASCs in comparison to BM from one of the donors 
as it did for the other two.
Osteogenic differentiation of hASCs in vitro
ALP activity (Fig. 4b) was significantly greater in OM, 
in contrast to BM at 7 and 14 d. Furthermore, ALP 
activity in both BM and OM increased significantly 
from 7 to 14 d. However, ALP activity did not rise 
significantly from 14 to 21 d in either BM or OM. ALP 
activity varied between different donor cell lines and 
especially one donor cell line had higher ALP activity 
in comparison to the others.
 Total collagen amount did not vary notably among 
BM and OM groups at 7, 14 or 21 d (Fig. 4c). Collagen 
amount increased in both study groups slightly 
from 7 to 14 d; however, collagen amount seemed to 
decline from 14 to 21 d.
 hASCs produced a pronounced mineralised 
matrix on the composite in both BM and OM at 
14 and 21 d (Fig. 4e). Furthermore, they produced 
notably more mineralised matrix on the scaffold in 
comparison to hASCs seeded on cell culture plastic 
(2D) at 21 d (Fig. 4e). At 14 d there was no difference 
between BM and OM. However, at 21 d, the mineral 
amount in OM was significantly larger than that in 
BM (Fig. 4d).
 Immunocytochemical staining of COL-I was 
conducted at 7, 14 and 21 d. In BM, COL-I expression 
was modest at all time points (Fig. 5a). However, in 
OM, a clear development of a collagenous matrix 
was seen during the 3-week experiment: at 7 d, 
cells were producing COL-I; at 14 d, cells were still 
producing COL-I and had also excreted COL-I to the 
extracellular matrix (ECM); at 21 d, there was a strong 
extracellular COL-I matrix seen in the representative 
image (Fig. 5a). In addition to COL-I, OCN was 
also stained at 14 and 21 d. OCN was expressed in 
both BM and OM at both time points; however, the 
staining was slightly stronger in OM at both time 
points (Fig. 5b).
Fig. 3. Viability of hASCs in β-TCP/PLCL composites. Representative images of live/dead stained hASCs 
cultured in β-TCP/PLCL composites in BM or OM after 7, 14 and 21 d in culture. Scale bar: 500 µm. 
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 qRT-PCR analysis for osteogenic genes ALP, 
RUNX2a, OSX and DLX5 was conducted at 7, 14 and 
21 d. Relative gene expression did not significantly 
differ in BM in comparison to OM during the 
experiment, although, the expression of RUNX2a (p 
values between groups at 7 d: 0.394; 14 d: 0.078; 21 d: 
0.310) and OSTERIX (p values between groups at 7 d: 
0.394; 14 d:0.123; 21 d: 0.240) was higher in OM as 
compared to BM at all time points (Fig. 6).
Bone regeneration within composites in rabbit 
femur defects
Bone was already able to grow on the surface as well 
as form inside the composite at 4 weeks (Fig. 7). The 
increased bone growth was observed on the surface 
and inside the composite at 12 and 24 weeks. In the 
4-week µCT and histological staining images, some 
bone formation could be seen beyond the original 
bone margins, which was most likely a periosteum-
induced reaction and not bone formation induced 
by the implant. Histological staining showed 
no signs of fibrous tissue or formation of cysts 
during the 24 weeks. µCT imaging confirmed the 
histological staining results. In addition, especially 
the representative µCT images at 24 weeks showed 
that the composite had degraded as compared to 4- 
and 12-week images (Fig. 7).
Discussion
Composites consisting of calcium phosphates and 
synthetic polymers have presented promising results 
in bone engineering applications and it has been 
Fig. 4. hASC culture and differentiation in β-TCP/PLCL composites. (a) Cell numbers at 7, 14 and 21 d. 
(b) ALP activity at 7, 14 and 21 d. (c) Total soluble collagen amount at 7, 14 and 21 d. (d) Quantitative 
mineralisation results after 14 and 21 d. (e) Representative images of mineral-stained cell-scaffold constructs 
after 14 and 21 d and of hASC cultures on cell culture plastic (2D) after 21 d. Stained blank scaffold without 
seeded cells is presented on the left of 21 d OM scaffold (scaffold Ø = 8 mm; well Ø = 15.5 mm). Statistical 
significance indicated as a p ≤ 0.001 or b p < 0.05 (n = 9).
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suggested that among biomaterials, composites are 
the most promising strategy for bone regeneration 
(de Misquita et al., 2016). ScCO2 processing is a very 
interesting processing method for polymeric tissue 
engineering structures as it is totally non-toxic, cost 
effective and has low critical parameters (TC: 304 K; 
PC: 7.5 MPa) enabling the addition of biomolecules, 
such as bone morphogenetic protein 2 (BMP-2), into 
the structure during processing (Duarte et al., 2013). 
The study aim was to manufacture a composite with 
high β-TCP content, with porosity similar to that of 
human cancellous bone. In scCO2 processing, the 
higher ceramic content decreases the porosity and 
increases the average pore size of the composite 
(Mathieu et al., 2006). Moreover, 5 wt% β-TCP content 
has been suggested to be the upper limit in order 
to obtain a homogenous and interconnected pore 
structure (Mathieu et al., 2006). In contrast to previous 
studies, it was possible, for the first time, to create a 
composite with 50 wt% β-TCP content with porosity 
as high as 65-67 % and average pore size of 380 µm 
by using scCO2. Previously, Mathieu et al. (2006) 
manufactured polylactide (PLA)/β-TCP composites 
by scCO2 with 74 % porosity but with only 10 % 
ceramic content. Moreover, Diaz-Gomez et al. (2017) 
reported PCL/fibroin/hydroxyapatite (70/20/10 %) 
F i g .  5 .  I m m u n o c y t o c h e m i c a l 
staining of osteogenic markers in 
hASCs in β-TCP/PLCL composites. 
R e p r e s e n t a t i v e  i m a g e s  o f 
immunocytochemical staining of (a) 
COL-I (green) after 7, 14 and 21 d in 
culture and (b) OCN (green) after 14 
and 21 d in culture. Nuclei are stained 
in blue. Scale bar: 100 µm.
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composites processed by using scCO2 with average 
porosity of 69.7 %.
 Another challenge related to manufacturing 
polymer-ceramic composites by using scCO2 is that 
the otherwise homogeneously distributed ceramic 
granules are covered by a polymer surface. To 
the authors’ knowledge, this was the first study 
overcoming this problem by using a dynamic 
compression treatment for the composites conducted 
in an aqueous environment at 37 °C. The treatment 
tore the polymer surface and β-TCP granules 
protruded on display as shown in the SEM images. 
The display of the β-TCP granules on the composite 
surface is highly important for the early interaction 
of the composite with cells and tissues, because PLCL 
lacks biological binding sites (Jeong et al., 2008; Wang 
et al., 2016) whereas β-TCP has the ability to bind to 
bone tissue (Barrere et al., 2006; Chatterjea et al., 2013) 
and induce osteogenic differentiation of mesenchymal 
stem cells (Marino et al., 2010). In addition, as the 
compression treatment tore additional holes in the 
PLCL pore surfaces, it increased the micro porosity 
and interconnectivity of the composites.
 The modulus of the composite was more similar 
to the modulus of cartilage (2.4-10 MPa) (Beck et al., 
2016) than to that of trabecular bone (10.75-13.66 GPa) 
(Peters et al., 2018), thus mimicking the soft callus 
formed during natural bone healing. Therefore, a 
bone defect treated with this composite would still 
require additional fixation to restrain the defect 
site. The closest comparable clinically approved 
composite material to the study composite is the 
bone void filler chronOSTM Strip from DePuy Synthes, 
which comprise PLCL and β-TCP granules. The 
compression strength of the β-TCP/PLCL composite 
analysed dry at RT was 1.1 MPa at 20 % strain and 
3 MPa at 50 % strain. The compressive strength of the 
chronOS® β-TCP granules is approximately 5 MPa 
(product manual of chronOS®), which is of the same 
order as the strength of the composite described in the 
current study. However, to the authors’ knowledge, 
the strength of the composite chronOSTM Strip has 
not been reported. Shikinami et al. (2006) compared 
different P(D/L)LA-based composites and reported 
the compression strength of 5.4 MPa for a porous 
β-TCP/ P(D/L)LA (weight ratio 70/30) analysed at 
RT. Moreover, Mathieu et al. (2006) reported the 
compression strength of approximately 3.5 MPa for 
a porous P(L)LA/β-TCP (weight ratio 90/10) composite 
also analysed dry at RT. As the requirements for 
an ideal bone substitute are highly demanding, the 
development of a scaffold may require compromising 
between achieving good cell and tissue response, 
desirable mechanical as well as user-friendly 
properties (Turnbull et al., 2017).
 The compression treatment significantly decreased 
both modulus and strength at 20 and 50 % strain, when 
samples were tested dry at RT. However, the aqueous 
Fig. 6. Relative gene expression of osteogenic genes in hASCs in β-TCP/PLCL composites. (a) ALP, (b) 
RUNX2a, (c) OSTERIX and (d) DLX5. Results (n = 6) are expressed relative to hRPLP0 and 7 d BM result. 
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environment at 37 °C, simulating the physiological 
environment, diminished these differences. This is 
due to PLCL’s glass transition temperature, which 
is between 21 and 22 °C (Ahola et al., 2013). β-TCP 
particles were not able to reinforce the porous 
composite matrix because the polymer chains seemed 
to be mobile at 37 °C, making the composite highly 
elastic. During incubation at 37 °C, both intact and 
pre-compressed composites started to recover from 
the initial drop of modulus and strength, as there 
was a rise from 1 h to 7 d at 37 °C. van der Pol et al. 
(2010) proposed that increasing the amount of β-TCP 
over 5 wt% in a scCO2-processed composite would 
make the composite more brittle and make it lose its 
ability to sustain any deformation. However, present 
results contradicted this suggestion. The increase in 
modulus between 1 h and 7 d at 37 °C was likely to be 
related to the reorganisation of the polymer matrix, 
e.g. crystallisation or an aging type phenomenon in 
aqueous environment at 37 °C, enabling the polymer 
chains to organise towards energetically more stable 
conformations (Pan et al., 2007; Zong et al., 1999). 
However, within limits of the present study, the true 
mechanism could not be determined.
 By monitoring the hydrolytic degradation both in 
vitro and in vivo, the aim was to define how accurately 
the in vitro degradation extrapolated to the situation 
in vivo. Because the degradation characteristics may 
depend e.g. on the polymer or the manufacturing 
method, the molecular degradation profile in vitro 
may model relatively accurately the degradation in 
vivo (Weir et al., 2004) or differ significantly (Koepp 
et al., 2004). The results showed that the hydrolytic 
degradation of the scCO2-foamed β-TCP/PLCL 
composite and the following degradation-dependent 
structural changes could be studied with very good 
accuracy in the in vitro model. The small differences 
in the degradation rate during the first 4 weeks could 
be related to the β-TCP content, which slows down 
the hydrolytic degradation by neutralising the acidic 
degradation products of lactide-based polymers 
(Niemelä, 2005). Previously, the same polymer and 
composite with β-TCP content were studied in vitro 
as non-foamed blocks (Ahola et al., 2013). Despite the 
different initial molecular weight but similar residual 
monomer content, the molecular weight was similar 
after 12 weeks of incubation at 37 °C (Ahola et al., 
2013) to that of the present foamed scaffolds.
 Results showed that the composites were 
cytocompatible in vitro, as hASC viability was 
very high, with only some dead cells, as observed 
by live/dead staining. Both live/dead staining and 
cell proliferation analysis showed that hASCs 
proliferated more when cultured in OM as compared 
to BM, as expected according to previous results with 
hASCs (Kyllönen et al., 2013a; Tirkkonen et al., 2013; 
Vanhatupa et al., 2015).
 Osteogenic differentiation of hASCs in composites 
was demonstrated by using various methods. 
Induction of ALP activity clearly occurred in BM 
and OM, even though the level of ALP activity was 
significantly higher in OM than in BM at 7 and 14 d. 
ALP activity as well as ALP expression peaked at 
14 d, as ALP expression is related to the matrix 
maturation phase of bone ECM development (Lian 
et al., 2012). Moreover, total soluble collagen amount 
was generally very similar in both BM and OM. 
Collagen amount was only slightly larger in OM at 
7 and 21 d as compared to BM. The slight decrease 
in soluble collagen from 14 to 21 d might be due to 
the development of osteogenic ECM. Mineralised 
collagen fibrils are the elementary building blocks 
Fig. 7. Bone formation in rabbit femora. Representative images of MGT-stained histological samples (scale 
bar 1 mm) from rabbit femora with implanted composites and corresponding µCT imaging (scale bar 2 mm) 
4, 12 and 24 weeks after implantation. * indicating periosteum-induced bone formation. 
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of bone (Nair et al., 2013) and the mineralisation of 
collagen fibrils may affect the solubility of collagen 
during soluble collagen analysis. Moreover, dense 
COL-I matrix promotes the osteogenic differentiation 
of mesenchymal stem cells attaching to it (Buxton et 
al., 2008). As alizarin red staining already confirmed 
the formation of a strong mineralised matrix in both 
BM and OM at 14 d and the immunocytochemical 
staining of COL-I was especially strong in OM at 
14 and 21 d, it is possible that mineralised collagen 
matrix, typical of bone development, had developed 
in cell cultures. In addition, the detection of the late 
osteogenic marker OCN by immunocytochemical 
staining confirmed the late osteogenic differentiation 
of hASCs in the composites (Lian et al., 2012). The 
expression of osteogenic genes was in line with the 
literature concerning bone development, as ALP and 
RUNX2a expression peaks are related to the early 
phase of differentiation whereas OSTERIX expression 
peaks to the late phase of differentiation (Lian et 
al., 2012). Moreover, when comparing the formed 
mineralised matrix on the scaffold in BM to that on 
the 2D control in BM, the composite itself seemed 
to induce osteogenic differentiation of hASCs even 
without the addition of osteogenic supplements.
 Bone regeneration within composites implanted in 
a rabbit distal femur defect model was demonstrated 
in a 24-week study. During implantation, the 
composite proved to be easy to handle and implant 
due to its elasticity and ability to recover after 
compression. Poly(L-lactide) implants (Pihlajamäki 
et al., 2006) and composites (van der Pol et al., 2010) 
have been shown to induce an inflammatory reaction 
due to acidic degradation products leading to the 
development of a fibrous capsule around the implant. 
However, the femur defect model demonstrated that 
the biocompatibility of the β-TCP/PLCL composite 
was good, as no formation of fibrous layer, cysts or 
infection was detected in any of the animals during 
the 24-week study. Moreover, the composite was 
shown to be osteoconductive as, according to the 
MGT staining and µCT images, bone was already 
able to grow on the surface of the composite and 
infiltrate inside the porous structure at 4 weeks. In 
contrast to the present results, van der Pol et al. (2010) 
showed that a PLA/β-TCP (95/5 wt%) composite 
manufactured by scCO2 processing induces the 
formation of a clear fibrous layer between the implant 
and mineralised tissue at 8 and 16 weeks in sheep 
femur defects. In concordance with the present 
results, Pihlman et al. (2018) studied the same porous 
β-TCP/PLCL composites and demonstrated the 
osteoconductivity and ingrowth of bone and vascular 
tissue in a rabbit calvarial defect model. Moreover, 
the β-TCP/PLCL composite gives structural support 
and blocks the surrounding soft tissues from bulging 
into the defect (Pihlman et al., 2018). Also, Pihlman 
et al. (2018), in their in vivo study, concluded that the 
mouldable and resilient composite is easier to use in 
clinics in contrast to most available products used for 
bone substitutes.
Conclusions
A highly porous, biodegradable, elastic and easy-
to-handle β-TCP/PLCL composite to serve as a bone 
substitute was created. To the authors’ knowledge, 
the present study was the first one reporting a 
composite manufactured by scCO2 processing with 
a high ceramic content (50 wt%) and porosity as 
high as 65-67 %. Furthermore, β-TCP particles in the 
processed composites were uncovered by using a 
dynamic compression treatment.
 The β-TCP/PLCL composite was cytocompatible 
and supported osteogenic differentiation of hASCs 
in vitro. The formation of a collagenous mineralised 
matrix already after 3 weeks in vitro was an especially 
clear indication of the composite’s potential as a bone 
substitute. Furthermore, the rabbit femur defect 
model showed that the β-TCP/PLCL composite was 
biocompatible, as it did not elicit the formation of 
fibrous capsule, cysts or infection. Finally, the β-TCP/
PLCL composite was osteoconductive, as bone tissue 
was already able to grow on the surface and inside 
the scaffold at 4 weeks. To conclude, the β-TCP/PLCL 
composite foamed by using scCO2 is a very promising 
bone substitute material and a potential candidate for 
use in clinics.
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Discussion with Reviewers
Ryan Porter: Much attention has been paid to 
the compressive strength of potential bone graft 
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substitutes. However, existing composite scaffolds 
with the porosity needed for osteoconduction do 
not approach the modulus required to replace lost 
bone function and avoid the need for bone fixation – 
particularly for lower extremity defects. If immediate 
restoration of bone mechanical properties is not a 
design goal, what factors determine the strength 
needed of candidate scaffolds for bone repair? Would 
this differ for grafts used in maxillofacial versus long 
bone defects?
Authors: The main aims in composite development 
are optimal porosity, biocompatibility and 
osteoconductivity. In addition, easy intra-operative 
tailoring is highly important, as, for instance, ceramics 
are not easy to handle or tailor during a surgery, 
which hinders surgeons’ work. With that said, 
future efforts aim to improve composite mechanical 
properties to create a composite with similar modulus 
to subchondral spongiosa. The requirements for 
mechanical strength of the scaffold are, of course, 
lower in maxillofacial defects in comparison to long 
bone defects and, therefore, the composite described 
in the study is suitable for non-load bearing sites.
Ryan Porter: Supercritical CO2 has also been used 
for biomaterial sterilisation processes, including 
bone allografts. Was the γ-irradiation step included 
for precautionary measures? Would both steps be 
required in a good manufacturing practice (GMP) 
manufacturing protocol for the proposed composite?
Authors: It is true that the processing method can 
also be used as a sterilisation method. γ-irradiation 
sterilisation was used for precautionary measures 
and because it is the commonly used and highly 
trusted sterilisation method among clinical 
products. The composite is classified as a medical 
device and, therefore, there is no need for a GMP-
level manufacturing protocol but an ISO13485 
manufacturing protocol is sufficient.
Ryan Porter: What might be the challenges to clinically 
translate bone graft alternatives manufactured using 
supercritical CO2?
Authors: These are highly important matters when 
developing a clinical product. The challenges in 
clinical translation of scCO2-processed structures are 
related to producing a homogenous pore structure in 
a reproducible manner. Furthermore, the scalability 
of the processing is another challenge to overcome 
in case of a large-scale production.
Pamela Habibovic: A problem of the in vitro 
experiments is the (partially strong) osteogenic 
differentiation in BM samples. This could indicate 
pre-differentiation of the used cells, pointing towards 
an activation of differentiation by the material itself 
or problems in the assays. This could be clarified by 
including data of suitable control groups in the results 
section, e.g. cells cultured in BM and OM on tissue 
culture plastic etc..
Authors: The reason for not using a 2D well plate 
control was the challenge related to the differences 
between experimental setups in 3D and 2D. 
Due to these differences, e.g. notable differences 
in cell seeding density and cell attachment, the 
results between the two setups would not be fully 
comparable.
Editor’s note: The Scientific Editor responsible for 
this paper was Joost de Bruijn.
